Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

[powerpress]

Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer. 

[powerpress]

Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.

[powerpress]

Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement.

Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years. 

[powerpress]

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

[powerpress]

Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

[powerpress]

Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.

[powerpress]